Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03962465
Recruitment Status : Recruiting
First Posted : May 24, 2019
Last Update Posted : September 11, 2020
Sponsor:
Collaborators:
Pfizer
Vanderbilt University
University of Wisconsin, Madison
Virginia Commonwealth University
Information provided by (Responsible Party):
Michael Douvas, MD, University of Virginia

Tracking Information
First Submitted Date  ICMJE May 22, 2019
First Posted Date  ICMJE May 24, 2019
Last Update Posted Date September 11, 2020
Actual Study Start Date  ICMJE November 22, 2019
Estimated Primary Completion Date January 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 23, 2019)
  • Characterization of Adverse Events (CTCAE version 5) [ Time Frame: All adverse events occurring through 30 days following last dose of inotuzumab ozogamicin. ]
    A characterization of all adverse events experienced by patients receiving these drug combinations. Also, any SAEs deemed related to study treatment, including veno-occlusive disease, will be captured at any time while the participant is on-study.
  • Dose-limiting toxicities [ Time Frame: From initiation of inotuzumab ozogamicin through 30 days following the last dose of inotuzumab ozogamicin ]
    The number of dose-limiting toxicities will be used to determine the maximum tolerated dose combination for these combinations of drugs
  • Informative course of treatment [ Time Frame: For each participant, up to the 29 days of study treatment ]
    Percent of patients that receive enough treatment to be informative to the study
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL
Official Title  ICMJE Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Younger Adults Ages 18-55 With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Brief Summary In the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to younger adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Two re-induction regimens will be tested (one without pegaspargase and one including pegaspargase) and participants will be followed for disease status, allogeneic hematopoietic cell transplant (allo HCT), veno-occlusive disease following allo HCT, and overall survival.
Detailed Description Inotuzumab ozogamicin has been studied as a single agent in refractory and relapsed ALL. In the relapsed setting, inotuzumab ozogamicin has been shown to achieve complete remission (CR) in 81% of patients and minimal residual disease (MRD) negativity in 78% of patients who achieve CR. In the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to younger adults with relapsed or refractory B-cell ALL. Two re-induction regimens will be tested. The first regimen is a 3-drug regimen comprised of prednisone, vincristine, and daunorubicin. The second is a 4-drug regimen comprised of prednisone, vincristine, daunorubicin, and pegaspargase. Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-ARA-C) will be included for central nervous system (CNS) prophylaxis with both the 3-drug and 4-drug regimens. We hypothesize that combining inotuzumab ozogamicin with these regimens is safe and will improve CR rates, successful transition to allo HCT, and overall survival in younger adults with relapsed or refractory B-ALL.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:
This is an early-phase study evaluating the safety of inotuzumab ozogamicin administered in combination with a 3-drug and 4-drug re-induction regimen in participants with relapsed or refractory B-ALL. The trial is planned to first determine the maximum tolerated dose (MTD) of the 3-drug re-induction regimen in Part 1 and then to determine the MTD of the 4-drug re-induction regimen (including pegaspargase) in Part 2.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE B-cell Acute Lymphoblastic Leukemia
Intervention  ICMJE
  • Drug: Inotuzumab ozogamicin
    By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
    Other Name: Besponsa
  • Drug: Prednisone Pill
    Taken daily days 1-28 by mouth
    Other Name: Deltasone
  • Drug: Daunorubicin
    By IV, given on days 1, 8, 15, and 22
    Other Names:
    • Cerubidine
    • daunomycin
    • rubidomycin
  • Drug: Vincristine
    By IV, given on days 1, 8, 15, and 22
    Other Names:
    • Oncovin
    • Vincasar
    • Leurocristine
  • Drug: Cytarabine
    Intrathecal, administered on day 1 only
    Other Names:
    • Ara-C
    • Cytosar-U
  • Drug: Methotrexate
    Intrathecal, administered on days 8 and 29
    Other Names:
    • Otrexup
    • Rasuvo
    • Rheumatrex
    • Trexall
    • MTX
    • Amethopterin
  • Drug: Pegaspargase
    By IV, given on day 4
    Other Name: Oncospar
Study Arms  ICMJE
  • Experimental: 3-drug re-induction regimen with inotuzumab

    One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.

    Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.

    IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)

    Interventions:
    • Drug: Inotuzumab ozogamicin
    • Drug: Prednisone Pill
    • Drug: Daunorubicin
    • Drug: Vincristine
    • Drug: Cytarabine
    • Drug: Methotrexate
  • Experimental: 4-drug re-induction regimen with inotuzumab

    One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.

    Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.

    IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)

    Interventions:
    • Drug: Inotuzumab ozogamicin
    • Drug: Prednisone Pill
    • Drug: Daunorubicin
    • Drug: Vincristine
    • Drug: Cytarabine
    • Drug: Methotrexate
    • Drug: Pegaspargase
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 23, 2019)
36
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 30, 2025
Estimated Primary Completion Date January 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Diagnosed with CD-22 positive* B-cell Acute Lymphoblastic Leukemia or B-cell Lymphoblastic Lymphoma (Philadelphia chromosome negative) * For the purposes of this study, CD-22 positive is defined as at least 60% positive by flow cytometry or immunohistochemistry.
  4. Body mass index (BMI) < 35 (BMI = weight in kg/(height in meters)^2)
  5. Male or female, aged 18-55 years
  6. ECOG performance status of 0-2
  7. Left ventricular ejection fraction > 45% measured by echocardiogram or MUGA
  8. Either relapsed following remission after initial induction therapy or refractory to induction therapy
  9. Adequate organ function, including serum creatinine ≤ 1.6 mg/dL or creatinine clearance < 50 ml/min by Cockgroft-Gault formula, bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's disease), AST, ALT and alkaline phosphatase ≤ 3 x upper limit of normal
  10. For females of reproductive potential: negative pregnancy test
  11. For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 1 year after the end of study treatment
  12. Agreement to adhere to Lifestyle Considerations throughout study duration and for 1 year following last study treatment.

Exclusion Criteria:

  1. Requires concomitant therapeutic anticoagulation (e.g. warfarin, low molecular weight heparin, direct oral anticoagulant) or any medication included in the restricted concomitant medications
  2. Past receipt of a total of ≥ 300 mg/m^2 doxorubicin equivalents (600 mg/m^2 daunorubicin, 60 mg/m^2 idarubicin, 75 mg/m^2 mitoxantrone)
  3. Current or past history of pancreatitis
  4. QT interval on electrocardiogram (ECG) > 0.45 by Framingham formula
  5. Known congestive heart failure
  6. Known allergy to asparaginase (only an exclusion criteria for participants enrolling in part 2)
  7. Presence of central nervous system (CNS) disease
  8. Pregnancy or lactation
  9. Chronic liver disease including chronic active hepatitis and/or cirrhosis
  10. Active Hepatitis B virus (HBV) by core antibody, surface antigen (HBsAg) or viral load
  11. Active Hepatitis C virus (HCV) (positive antibody test confirmed by viral load if antibody test is positive)
  12. Known history of infection with Human Immunodeficiency Virus (HIV)
  13. Active or uncontrolled infections
  14. Abnormal baseline hepatic ultrasound (including Dopplers)
  15. Prior allogeneic stem cell transplant
  16. Prior use of inotuzumab ozogamicin
  17. Known diagnosis of hemochromatosis with iron overload
  18. Prior CAR-T cell therapy
  19. Treatment with steroids or hydroxyurea for more than 7 days within the 2 weeks prior to registration
  20. Gastrointestinal tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease, or inability to swallow medications.
  21. Philadelphia chromosome positive B-cell ALL
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Katie Rea, RN 434-924-8574 KAW3J@hscmail.mcc.virginia.edu
Contact: April Muniz 434 243 5350 am4pf@virginia.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03962465
Other Study ID Numbers  ICMJE 21417
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Michael Douvas, MD, University of Virginia
Study Sponsor  ICMJE University of Virginia
Collaborators  ICMJE
  • Pfizer
  • Vanderbilt University
  • University of Wisconsin, Madison
  • Virginia Commonwealth University
Investigators  ICMJE
Principal Investigator: Michael Douvas, MD University of Virginia
PRS Account University of Virginia
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP